

**Amendments to the Specification:**

Please replace paragraph [0019] beginning at page 8, line 3, with the following:

--[0019] **Figure 1.** Diagram of the *XAGE-1* transcripts. The complete nucleic acid sequence of XAGE-1 shown, with untranslated 5' and 3' ends, is ~~SEQ ID NO:1~~ SEQ ID NO:45. The polyadenylation signal is *italicized* and in *bold*. The translation stop and start codons are indicated in *bold*. Primers are indicated by arrows and by name, and the transcriptional start sites are indicated by "star burst" symbols above the nucleotide sequence. Intron / exon boundaries are indicated by vertical lines capped with a horizontal line (i.e., a "T" shaped symbol). The nucleic acid and protein sequences for xage-1 p9 are SEQ ID NOS:1 and 2, and for xage-1 p16 are SEQ ID NOS:3 and 4, respectively.--

Please replace paragraph [0038] beginning at page 13, line 29, with the following:

--[0038] "Xage-1 p9" and "p9" refer to a protein expressed from the XAGE-1 gene having a relative molecular weight of about 9 kD. The nucleic acid sequence (SEQ ID NO:1) encoding the xage-1 9 kD protein and the amino acid sequence (SEQ ID NO:2) of xage-1 p9, are set forth in Figure 1. The nucleic acid sequence (SEQ ID NO:1) encoding the protein starts with nucleotide 284 312 of the nucleotide sequence shown in Figure 1; the amino acid sequence (SEQ ID NO:2) starts at the methionine found at position 66 of the amino acid sequence shown in that Figure.--

Please replace paragraph [0039] beginning at page 14, line 3, with the following:

--[0039] "Xage-1 p16" and "p16" refer to a protein expressed from the XAGE-1 gene having a calculated molecular weight of about 16.3 kD. The nucleic acid sequence encoding xage-1 p16 (SEQ ID NO:3) and the amino acid sequence of xage-1 p16 (SEQ ID NO:4), are set forth in

Figure 1. The nucleic acid sequence (SEQ ID NO:3) encoding the protein starts with nucleotide [[1]] 97 of the nucleotide sequence shown in Figure 1; the amino acid sequence (SEQ ID NO:4) starts at the methionine found at position 1 of the amino acid sequence in that Figure.--

Please replace paragraph [0140] beginning at page 36, line 8, with the following:

--[0140] The present invention provides isolated immunogenic peptides of fifty amino acid residues or fewer, comprising the amino acid sequence  $X_1X_2X_3PSAPSPX_4$  (SEQ ID NO:5), wherein  $X_1$  can be any amino acid and is preferably G or Y;  $X_2$  can be selected from the group consisting of L, M, A, I, V, and T, with L and M being preferred;  $X_3$  can be a hydrophobic residue, M or A; and  $X_4$  may be V, M, L, A, I, or T, and is preferably V, or comprising an amino sequence of SEQ ID NOS:38-40, or both an amino acid sequence of SEQ ID NO:5 and one or more of SEQ ID NOS:38-40. To be considered a peptide of this invention, the peptide must bind to HLA-A2 and, when presented in conjunction with HLA-A2, induce cytotoxic T-cells to lyse cells expressing XAGE-1. These immunogenic peptides may be synthesized by any of the techniques that are known to those skilled in the peptide art, including recombinant DNA techniques.--

Please replace paragraph [0173] beginning at page 45, line 3, with the following:

--[0173] To find potential immunogenic peptide derived from XAGE-1, the xage-1 p16 amino acid sequence was searched for potential HLA-A2 binding peptides using a computer program. A known HLA-A2 binding motif was used to determine putative immunogenic peptides. Three such putative peptides were selected: (a) a peptide containing residues 14-23 of xage-1 ("xage-1 14", SEQ ID NO:6), (b) a peptide containing residues 33-42 of xage-1 ("xage-1 33", SEQ ID NO:32), and (c) a peptide containing residues 57-66 of xage-1 ("xage-1 57", SEQ ID NO:33). *See*, Table 2, below. The peptides were then synthesized for study.--

Appl. No. 10/582,703

PATENT

Amdt. dated May 9, 2007

Reply to Notification of Missing Requirements of February 22, 2007

Please cancel the present "SEQUENCE LISTING", pages 1-16, for the parent application PCT/US04/14306 submitted June 12, 2006, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 16, at the end of the application.